Gondola Medical Technologies

Gondola Medical Technologies operates in medical devices, rehabilitation, home health care, and therapeutics, with a focused offering for mobility symptoms associated with neurological conditions, particularly Parkinson’s disease. Its differentiation in the available product information is the Gondola AMPS approach: brief mechanical pressure stimulation at specific points on both feet, delivered through devices intended for home use or healthcare-professional settings. The company describes the therapy as non-invasive and complementary to existing treatment, rather than a replacement. Its portfolio includes the Gondola Home Device for individualized home use and the Gondola Professional Device for clinical consultations. The website also cites clinical studies involving more than 300 people with Parkinson’s and outcomes such as walking speed, step length, gait symmetry, and balance. The company’s listed categories place it among broader rehabilitation and medical-device providers, but its specific foot-stimulation therapy gives it a distinct product focus within that landscape.

Founded in 2011, Gondola Medical Technologies developed a specialized medical-device business around AMPS therapy and its use for mobility symptoms associated with Parkinson’s disease. The recorded financing history shows a grant dated Dec 1, 2018, a corporate round on Oct 15, 2019 with no disclosed amount, and CHF 500,000 in debt financing from Foundation for Innovation and Technology (FIT) on Dec 21, 2020. The company’s stated growth signal reports an increase from five to 17 employees by 2020, suggesting a period of team expansion alongside financing and clinical-research activity. A Mar 29, 2021 milestone also drew attention to support for clinical research, followed by a Aug 27, 2021 profile of co-founder Francesco Cecchini and the company’s rehabilitation technology. These points indicate a trajectory centered on developing and supporting a targeted therapy, rather than documented rapid product-line expansion. The employee range currently recorded is 11–50, while the listed team information includes two current positions; those figures do not establish present-day headcount. Further assessment of growth would require current information on staffing, device adoption, and clinical or commercial milestones.